Last reviewed · How we verify

NCT03341845

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Status unknown Phase 2 Last updated 21 May 2018
What this trial tests

Phase 2 trial testing Axitinib in Renal Cell Carcinoma in 40 participants. Status unknown.

Timeline
28 March 2018
Primary endpoint
31 January 2023
31 January 2025

Quick facts

Lead sponsorThe Netherlands Cancer Institute
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date28 March 2018
Primary completion31 January 2023
Estimated completion31 January 2025
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting cytokine and chemokine signaling pathways for cancer therapy.
    Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
  2. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
    Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, et al · · 2019 · cited 124× · PMID 31138299 · DOI 10.1186/s40425-019-0621-1
  3. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
    Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071
  4. Product review: avelumab, an anti-PD-L1 antibody.
    Collins JM, Gulley JL. · · 2019 · cited 62× · PMID 30481100 · DOI 10.1080/21645515.2018.1551671
  5. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
    Karam JA, Msaouel P, Haymaker CL, Matin SF, et al · · 2023 · cited 45× · PMID 37164948 · DOI 10.1038/s41467-023-38342-7
  6. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
    Bæk Møller N, Budolfsen C, Grimm D, Krüger M, et al · · 2019 · cited 43× · PMID 31547602 · DOI 10.3390/ijms20194712
  7. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).
    Bex A, van Thienen JV, Schrier M, Graafland N, et al · · 2019 · cited 25× · PMID 31023100 · DOI 10.2217/fon-2019-0111
  8. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
    Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898

Verify or expand the search:

Other trials of Axitinib

Trials testing the same drug.

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03341845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing